OSLO, Norway, April 29, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light ...
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of a health economics abstract from the BRAVO study at the Society of Urologic Oncology 2025 Annual Meeting (SUO) ...
Please provide your email address to receive an email when new articles are posted on . Cystoscopies for recurrent UTIs yield little clinical benefit for patients both with and without high-risk ...
OSLO, Norway, Feb. 17, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder ...
The guidelines state that clinicians should offer blue light cystoscopy, if available, as an adjunct to traditional white light cystoscopy (WLC) to increase tumor detection and decrease recurrence.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback